3D Print Biotechnology and Neuroscience.

3D Bioprinting using Nano.

Image Posted on Updated on

 

Magnetic 3D bioprinting uses magnetic nanoparticles to 3D print cell structures. The magnetic nanoparticles are biocompatible they can be in contact with living cells without causing adverse effects. The process makes cells magnetic by tagging them with magnetic particles. Once the cells become magnetic, external magnetic forces are used to 3D printed the cells into specific cell structures.  A technique called magnetic levitation is used to levitate cells in a container using a magnet above the container. Levitation of the cells causes the cells to aggregate rapidly.

The first 3D bioprinting system was commercially made available by Nano3D Biosciences. This technology is targeted for use in the pharmaceutical industry.  This technology can be used for building simple cellular structures such as spheroids and rings as well as complex structures such as aortic valves.

 

Magnetic 3D bioprinting.

 

 

3D printing living tissue.

Image Posted on Updated on

 

Youtube Video: 3D Bioprinter

According to Organovo,” this is a medical research company headquartered in San Diego which designs and develops three-dimensional human tissue. The living 3D printed tissue can be used for testing drugs before giving the drugs to a real person. Organovo uses a proprietary bioprinting platform called NovoGen for 3D printing tissue.
Pharmaceutical companies conventionally perform testing on animals or on cells in Petri-dishes. Both methods of testing are very different from testing on a living person. Therefore several clinical trials fail when tried on the living person even if they were considered successful on animals or cells in petri-dish. Organovo technology bridges this gap by providing 3D tissue models that are much closer to a living person. Pharmaceutical companies can use the 3D tissues developed using this technology for testing.
In 2014 Organovo announced the commercial release of exVive3DTM Human Liver Tissue for preclinical drug discovery testing. In April 2015, Organovo presented results of 3D printing in vitro 3D kidney tissue at the 2015 Experimental Biology conference in Boston. In 2015 L’Oreal signed an agreement with Organovo to produce 3D-printed skin for use in testing cosmetics. The long-term goal of Organovo’s 3D bioprinting technology is to be able to create organs for transplantation.¨